SGO Winter Meeting | Conference

Antiangiogenics, ADCs Still Have Roles in Ovarian Cancer Treatment

January 20th 2019

For all the positive data associated with PARP inhibitors in patients with epithelial ovarian cancer who have known BRCA mutations and despite several agents winning FDA approval over the past few years, PARP inhibitors aren’t curing patients.

Westin Highlights the Evolving Role of PARP Inhibitors in Ovarian Cancer

January 19th 2019

Shannon Westin, MD, discusses the evolving role of PARP inhibitors in ovarian cancer, novel investigational agents, and the importance of molecular testing.

Dr. Suarez Mora On Sequential Sampling of IP Fluid During Chemotherapy

January 19th 2019

Adria Suarez Mora, MD, second-year fellow at UPMC Magee-Womens Hospital, discusses how sequential sampling of intraperitoneal fluid during chemotherapy help better define the immunogenic effects of the treatment.

Dr. Essel on Quantitative Computed Tomography Image Feature Analysis in Gynecologic Cancers

January 19th 2019

Kathleen G. Essel, MD, gynecologic oncology fellow at the University of Oklahoma Health Science Center with the Stephenson Cancer Center, discusses the benefits of using quantitative computed tomography image feature analysis to predict response to immune checkpoint inhibitors in patients with gynecologic cancers.

Dr. Lefkowits Addresses Misconceptions About Palliative Care Integration

January 19th 2019

Carolyn Lefkowits, MD, gynecologic oncologist, and palliative care doctor, at the University of Colorado, addresses common misconceptions regarding palliative care integration.

Investigators Still Seeking Options Beyond PARP Inhibitors in Ovarian Cancer

January 19th 2019

Targeted therapy is effectively established as an option for patients with ovarian cancers. However, beyond PARP inhibition in the BRCA-mutated or homologous recombination deficient population, questions remain about how to best treat these patients.

Immunotherapy Agents Could Improve Survival in Advanced Cervical Cancer

January 19th 2019

The prognosis for women with recurrent or metastatic cervical cancer after treatment failure is notoriously poor, but immunotherapy agents may offer longer survival for this population.

Dr. Kurnit on Adjuvant Chemotherapy Regimens in Mucinous Ovarian Cancer

January 19th 2019

Katherine Kurnit, MD, OBGYN oncology fellow at the University of Texas MD Anderson Cancer Center, compares the benefit of gastrointestinal-based versus gynecologic-based adjuvant chemotherapy regimens in patients with mucinous ovarian cancer.

Adjuvant GI-Based Chemo Regimens Improve Survival in Mucinous Ovarian Cancer

January 19th 2019

Results from a recent retrospective study indicate that treatment with a gastrointestinal-based adjuvant chemotherapy regimen may be more beneficial than that of a gynecologic-based one in patients with mucinous ovarian cancer.

Genomic Testing Has Impact on Treatment Decisions in Ovarian Cancer

January 18th 2019

Genomic testing to guide treatment decisions for women with ovarian cancer is in its early days. However, as more platforms become commercially available, physicians will need to understand the similarities and differences between tests.

Dr. Kalogera on Bowel Preparation Following Minimally Invasive or Open Hysterectomies

January 18th 2019

Eleftheria Kalogera, MD, MSc, instructor in Obstetrics and Gynecology, fellow in Gynecologic Oncology, in the department of Obstetrics and Gynecology, at Mayo Clinic College of Medicine, discusses the controversial topic of bowel preparation following minimally invasive or open hysterectomies.

Dr. Westin on Advances Made With PARP Inhibitors in Ovarian Cancer

January 18th 2019

Shannon N. Westin, MD, MPH, associate professor, The University of Texas MD Anderson Cancer Center, discusses advances made with PARP inhibitors in the ovarian cancer treatment paradigm.

PARP Combos May Represent Future in Frontline Maintenance Ovarian Cancer Setting

January 18th 2019

Several ongoing trials are examining combinations of PARP inhibitors and immunotherapy agents as frontline maintenance for patients with ovarian cancer.

Immunotherapy Combos on Horizon for Ovarian Cancer

February 11th 2018

Several phase III studies are exploring immunotherapy combinations with the potential to disrupt the systemic treatment paradigm for patients with ovarian cancer.

PARP Combinations Offer New Opportunities in Ovarian Cancer

February 11th 2018

PARP inhibitor combination regimens have the potential to enhance the relatively modest benefit offered by several monotherapy approaches used for the treatment of patients with ovarian cancer.

Dr. Backes on Pelvic Exenteration Surgery in Gynecologic Cancer

February 10th 2018

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses pelvic exenteration surgery for patients with gynecologic cancer.

Dr. Arend on the Rationale of Novel Combinations in Gynecologic Cancer

February 10th 2018

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the rationale behind novel combination strategies for patients with gynecologic cancer.

PARP Combos With Bevacizumab, Immunotherapy in Development for Ovarian Cancer Treatment

February 10th 2018

Rebecca C. Arend, MD, discussed novel combinations being investigated for the treatment of patients with ovarian cancer.

Expert Highlights PARP Inhibitor Advancements in Ovarian Cancer, Points to Future Combos

February 10th 2018

David O'Malley, MD, discusses the excitement surrounding PARP inhibitors for patients with ovarian cancer.

Immune Checkpoint Combinations Show Promise in Endometrioid Disease

February 10th 2018

Many endometrioid cancers express high RNA levels for multiple immune checkpoints, and this may allow physicians to treat these patients with combination immune therapies.